<p>The vaccine was recently approved by the EU and Austrailia. This type of meningitis is endemic in those areas, but extremely rare in the US. Novartis (the vaccine’s maker) targeted those markets first (not because it’s easier to get approved there).</p>
<p>This is a scary, albeit rare, disease whose outbreaks take a long time to burn itself out. The risk/reward ratio seems to tilt in favor of drastic action.</p>